Cabaletta Bio, Inc. Stock News

Regulatory News: Celyad SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), une société biotechnologique de stade clinique fo

Cabaletta Bio, Inc. (CABA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).

Cabaletta Bio, Inc. (CABA), a clinical stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today

PHILADELPHIA, May 27, 2020 -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies.

Cabaletta Bio, Inc. (CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today

Cabaletta Bio, Inc. (CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today

Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases

Cabaletta Bio is pioneering the use of CAAR-T cell therapies to potentially cure various autoimmune diseases. Autoimmunity is a large market, at least $100B, bu

New Strong Buy Stocks for April 27th

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

Cubist Systematic Strategies LLC acquired a new stake in Cabaletta Bio (NASDAQ:CABA) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund acquired 5,505 shares of

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th

Cabaletta Bio, Inc. (CABA) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Cabaletta Bio’s (NASDAQ:CABA) lock-up period will end on Wednesday, April 22nd. Cabaletta Bio had issued 6,800,000 shares in its IPO on October 25th. The total size of the offering was $74,800,000 b

Cabaletta Bio’s (NASDAQ:CABA) lock-up period is set to expire on Wednesday, April 22nd. Cabaletta Bio had issued 6,800,000 shares in its initial public offering on October 25th. The total size of th